Bessie A Young1, Erika Blacksher2, Kerri L Cavanaugh3, Barry I Freedman4, Stephanie M Fullerton2, Jeffrey B Kopp5, Ebele M Umeukeje3, Kathleen M West6, James G Wilson7, Wylie Burke2. 1. Department of Medicine, VA Puget Sound Health Care System, Division of Nephrology, and Kidney Research Institute, University of Washington, Seattle, Washington, USA. 2. Department of Bioethics and Humanities, University of Washington, Seattle, Washington, USA. 3. Division of Nephrology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA. 4. Department of Internal Medicine, Section on Nephrology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA. 5. Kidney Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland, USA. 6. Department of Bioethics and Humanities, University of Washington, Seattle, Washington, USA, westkate@uw.edu. 7. Department of Physiology and Biophysics, University of Mississippi, Jackson, Mississippi, USA.
Abstract
BACKGROUND: Apolipoprotein A1 (APOL1) gene variants occurring in people of West African descent contribute to the greater burden of kidney disease among African Americans. These variants are associated with increased risk of nondiabetic nephropathy, more rapid progression of chronic kidney disease, and shorter survival of donor kidneys after transplantation. However, only a minority of people with APOL1-associated risk develops kidney disease and specific clinical measures to address APOL1-associated risk are lacking. Given these uncertainties, we sought to engage members of the African American public in discussions with other stakeholders about the appropriate use of APOL1 testing. METHODS: Formative interviews with community members, researchers, and clinicians in Seattle WA, Nashville TN, and Jackson MS, provided baseline information about views toward APOL1 testing and informed the design of 3 community-based deliberations among African Americans. A national meeting held in March 2018 included 13 community members, 7 scientific advisors and 26 additional researchers, clinicians, bioethicists, patient advocates, and representatives from professional organizations and federal funding agencies. Using small break-out and plenary discussion, the group agreed on recommendations based on current knowledge about APOL1-associated risk. RESULTS: Meeting outcomes included recommendations to develop educational materials about APOL1 for community members and clinicians; to offer APOL1 research results to participants; and on the use of APOL1testing in kidney transplant programs. The group recommended against the routine offer of APOL1 testing in clinical care. Areas of disagreement included whether kidney transplant programs should require APOL1 testing of prospective living donors or bar individuals with APOL1 risk from donating kidneys and whether testing should be available on request in routine clinical care. CONCLUSION: We recommend continued discussion among stakeholders and concerted efforts to ensure active and informed participation of members of the affected community to guide research on APOL1 and kidney disease.
BACKGROUND:Apolipoprotein A1 (APOL1) gene variants occurring in people of West African descent contribute to the greater burden of kidney disease among African Americans. These variants are associated with increased risk of nondiabetic nephropathy, more rapid progression of chronic kidney disease, and shorter survival of donor kidneys after transplantation. However, only a minority of people with APOL1-associated risk develops kidney disease and specific clinical measures to address APOL1-associated risk are lacking. Given these uncertainties, we sought to engage members of the African American public in discussions with other stakeholders about the appropriate use of APOL1 testing. METHODS: Formative interviews with community members, researchers, and clinicians in Seattle WA, Nashville TN, and Jackson MS, provided baseline information about views toward APOL1 testing and informed the design of 3 community-based deliberations among African Americans. A national meeting held in March 2018 included 13 community members, 7 scientific advisors and 26 additional researchers, clinicians, bioethicists, patient advocates, and representatives from professional organizations and federal funding agencies. Using small break-out and plenary discussion, the group agreed on recommendations based on current knowledge about APOL1-associated risk. RESULTS: Meeting outcomes included recommendations to develop educational materials about APOL1 for community members and clinicians; to offer APOL1 research results to participants; and on the use of APOL1testing in kidney transplant programs. The group recommended against the routine offer of APOL1 testing in clinical care. Areas of disagreement included whether kidney transplant programs should require APOL1 testing of prospective living donors or bar individuals with APOL1 risk from donating kidneys and whether testing should be available on request in routine clinical care. CONCLUSION: We recommend continued discussion among stakeholders and concerted efforts to ensure active and informed participation of members of the affected community to guide research on APOL1 and kidney disease.
Authors: Giulio Genovese; David J Friedman; Michael D Ross; Laurence Lecordier; Pierrick Uzureau; Barry I Freedman; Donald W Bowden; Carl D Langefeld; Taras K Oleksyk; Andrea L Uscinski Knob; Andrea J Bernhardy; Pamela J Hicks; George W Nelson; Benoit Vanhollebeke; Cheryl A Winkler; Jeffrey B Kopp; Etienne Pays; Martin R Pollak Journal: Science Date: 2010-07-15 Impact factor: 47.728
Authors: Elaine Ku; Michael S Lipkowitz; Lawrence J Appel; Afshin Parsa; Jennifer Gassman; David V Glidden; Miroslaw Smogorzewski; Chi-Yuan Hsu Journal: Kidney Int Date: 2016-12-04 Impact factor: 10.612
Authors: Alex N Kasembeli; Raquel Duarte; Michèle Ramsay; Pulane Mosiane; Caroline Dickens; Thérèse Dix-Peek; Sophie Limou; Efe Sezgin; George W Nelson; Agnes B Fogo; Stewart Goetsch; Jeffrey B Kopp; Cheryl A Winkler; Saraladevi Naicker Journal: J Am Soc Nephrol Date: 2015-03-18 Impact factor: 10.121
Authors: Girish N Nadkarni; Christopher R Gignoux; Elena P Sorokin; Michelle Daya; Rayees Rahman; Kathleen C Barnes; Christina L Wassel; Eimear E Kenny Journal: N Engl J Med Date: 2018-12-27 Impact factor: 91.245
Authors: Barry I Freedman; Stephen O Pastan; Ajay K Israni; David Schladt; Bruce A Julian; Michael D Gautreaux; Vera Hauptfeld; Robert A Bray; Howard M Gebel; Allan D Kirk; Robert S Gaston; Jeffrey Rogers; Alan C Farney; Giuseppe Orlando; Robert J Stratta; Sumit Mohan; Lijun Ma; Carl D Langefeld; Donald W Bowden; Pamela J Hicks; Nicholette D Palmer; Amudha Palanisamy; Amber M Reeves-Daniel; W Mark Brown; Jasmin Divers Journal: Transplantation Date: 2016-01 Impact factor: 4.939
Authors: Teresa K Chen; Adrienne Tin; Carmen A Peralta; Lawrence J Appel; Michael J Choi; Michael S Lipkowitz; Cheryl A Winkler; Michelle M Estrella Journal: Clin J Am Soc Nephrol Date: 2017-10-19 Impact factor: 8.237
Authors: Cristian Riella; Tobias A Siemens; Minxian Wang; Rodrigo P Campos; Thyago P Moraes; Leonardo V Riella; David J Friedman; Miguel C Riella; Martin R Pollak Journal: Kidney Int Rep Date: 2019-03-20
Authors: Barry I Freedman; Wylie Burke; Jasmin Divers; Lucy Eberhard; Crystal A Gadegbeku; Rasheed Gbadegesin; Michael E Hall; Tiffany Jones-Smith; Richard Knight; Jeffrey B Kopp; Csaba P Kovesdy; Keith C Norris; Opeyemi A Olabisi; Glenda V Roberts; John R Sedor; Erika Blacksher Journal: J Am Soc Nephrol Date: 2021-04-14 Impact factor: 14.978
Authors: Margaret Berrigan; Jasmine Austrie; Aaron Fleishman; Kenneth P Tercyak; Martin R Pollak; Martha Pavlakis; Vinayak Rohan; Prabhakar K Baliga; Liise K Kayler; Thomas H Feeley; James R Rodrigue Journal: Am J Transplant Date: 2020-08-29 Impact factor: 8.086